Evidence map›Paper›PMID 34889531›Full record

ArticleNeuropsychopharmacology reports2022

Severe and long-lasting neuropsychiatric symptoms after mild respiratory symptoms caused by COVID-19: A case report.

Ryosuke Jozuka, Hiroki Kimura, Takashi Uematsu, Hidetsugu Fujigaki, Yasuko Yamamoto, Masato Kobayashi, Kazuya Kawabata, Haruki Koike, Toshiya Inada, Kuniaki Saito and 2 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Neuropsychopharmacology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Ryosuke JozukaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hiroki KimuraDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0002-0610-7904
Takashi UematsuDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hidetsugu FujigakiDepartment of Advanced Diagnostic System Development, Fujita Health University Graduate School of Health Science, Toyoake, Japan.
Yasuko YamamotoDepartment of Advanced Diagnostic System Development, Fujita Health University Graduate School of Health Science, Toyoake, Japan.
Masato KobayashiDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kazuya KawabataDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Haruki KoikeDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Toshiya InadaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0002-8427-5639
Kuniaki SaitoDepartment of Advanced Diagnostic System Development, Fujita Health University Graduate School of Health Science, Toyoake, Japan.
Masahisa KatsunoDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Norio OzakiDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Nagoya University · JPFujita Health University · JP

Funding

AMED JP21dk0307099AMED JP21dk0307103Japan Society for the Promotion of Science 21H02848
6 · The paper itself

Abstract

backgroundCoronavirus disease 2019 (COVID-19) is known to cause not only respiratory but also neuropsychiatric symptoms, which are assumed to be derived from a cytokine storm and its effects on the central nervous systems. Patients with COVID-19 who develop severe respiratory symptoms are known to show severe neuropsychiatric symptoms such as cerebrovascular disease and encephalopathy. However, the detailed clinical courses of patients with neuropsychiatric symptoms caused by mild or asymptomatic COVID-19 remain poorly understood. Here, we present a case of COVID-19 who presented with severe and prolonged neuropsychiatric symptoms subsequent to mild respiratory symptoms. CASE PRESENTATION: A 55-year-old female with COVID-19 accompanied by mild respiratory symptoms showed delusion, psychomotor excitement, and poor communication ability during quarantine outside the hospital. Considering her diminished respiratory symptoms, her neuropsychiatric symptoms were initially regarded as psychogenic reactions. However, as she showed progressive disturbance of consciousness accompanied by an abnormal electroencephalogram, she was diagnosed with post-COVID-19 encephalopathy. Although her impaired consciousness and elevated cytokine level improved after steroid pulse therapy, several neuropsychiatric symptoms, including a loss of concentration, unsteadiness while walking, and fatigue, remained.

conclusionsThis case suggests the importance of both recognizing that even apparently mild COVID-19-related respiratory symptoms can lead to severe and persistent neuropsychiatric symptoms, and elucidating the mechanisms, treatment, and long-term course of COVID-19-related neuropsychiatric symptoms in the future.

Indexed as

COVID-19Mental DisordersFatigueFemaleHumansMiddle AgedSARS-CoV-2case reportCOVID-19cytokinesencephalopathylong COVID

Identifiers

PMID34889531
PMCPMC8919122
OpenAlexW4200451150

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.